News release today:
Hestia Insight Inc. Appoints Advisory Board Member to Assist in Company Growth
NEW YORK, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced its appointment of an additional advisory board member to assist in the growth of the Company.
Dr. T.Z. (Ted) Chaung, a seasoned independent healthcare consultant with broad experience in healthcare industry startups, new drug development, venture capital, and business development, in both the Taiwan and U.S. healthcare sectors, has joined the Company’s advisory board.
“We are excited to welcome the addition of Dr. Ted Chaung to our Advisory Board,” stated Hestia Insight’s CEO and Chairman, Edward Lee. Mr. Lee continued, “Dr. Chaung is a world-class independent healthcare business development consultant, who during his accomplished professional career held high-level positions at pharmaceutical industry leaders including Merck & Company, San-Fu/Air Products-Taiwan, Hoffman-La Roche, Bristol-Myers Squibb Company, and China Chemical & Pharmaceutical Group. Prior to his illustrious professional career, Dr. Chaung attended such prestigious institutions as National Taiwan University, West Virginia University, and Massachusetts Institute of Technology. We look forward to utilizing Dr. Chaung’s impressive background and skill set to assist with the growth of Hesta Insight.”
About Hestia Insight Inc.
Hestia Insight Inc. (“Hestia Insight” and the “Company”) is focused primarily on the healthcare and biotech sectors through the Company’s two wholly owned operating subsidiaries, Hestia Investments Inc. (“Hestia Investments”), and HSTA Health Inc. (“HSTA Health”). Hestia Investments provides strategic consulting, medical supply sales and marketing support, management, and capital markets advisory services for select micro, small and medium sized companies within the healthcare and biotech sectors. HSTA Health provides healthcare management and patient services and develops new healthcare technologies for neurological and psychiatric disorders. The Company is positioned to make strategic acquisitions of emerging growth companies with unique sciences and technologies. The Company intends to pursue the acquisition and development of healthcare related technologies in the healthcare and biotech sectors through acquisition, licensing, or joint ventures. The Company will also consider a third avenue of investing in certain technologies. The Company entered the healthcare sector to explore emerging healthcare technologies, especially growth companies that own and develop unique sciences and technologies.
For more information about Hestia Insight, please visit the Company’s website: www.hestiainsight.com
Hestia Insight Investor Relations: investors.hestiainsight.com
Facebook: Hestia Insight Inc.
LinkedIn: Hestia Insight Inc.
Twitter: @HestiaInsight
Hestia Insight is subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended, and, in accordance with the Securities Exchange Act, the Company files periodic reports, documents, and other information with the SEC relating to our business, financial statements, and other matters. These filings are available to the public on the Commission’s website at http://www.sec.gov.
Investor Relations Contact:
Paul Knopick
Tel: 940.262.3584
Email: pknopick@eandecommunications.com
Hestia Insight Inc. Appoints Advisory Board Member to Assist in Company Growth
NEW YORK, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced its appointment of an additional advisory board member to assist in the growth of the Company.
Dr. T.Z. (Ted) Chaung, a seasoned independent healthcare consultant with broad experience in healthcare industry startups, new drug development, venture capital, and business development, in both the Taiwan and U.S. healthcare sectors, has joined the Company’s advisory board.
“We are excited to welcome the addition of Dr. Ted Chaung to our Advisory Board,” stated Hestia Insight’s CEO and Chairman, Edward Lee. Mr. Lee continued, “Dr. Chaung is a world-class independent healthcare business development consultant, who during his accomplished professional career held high-level positions at pharmaceutical industry leaders including Merck & Company, San-Fu/Air Products-Taiwan, Hoffman-La Roche, Bristol-Myers Squibb Company, and China Chemical & Pharmaceutical Group. Prior to his illustrious professional career, Dr. Chaung attended such prestigious institutions as National Taiwan University, West Virginia University, and Massachusetts Institute of Technology. We look forward to utilizing Dr. Chaung’s impressive background and skill set to assist with the growth of Hesta Insight.”
About Hestia Insight Inc.
Hestia Insight Inc. (“Hestia Insight” and the “Company”) is focused primarily on the healthcare and biotech sectors through the Company’s two wholly owned operating subsidiaries, Hestia Investments Inc. (“Hestia Investments”), and HSTA Health Inc. (“HSTA Health”). Hestia Investments provides strategic consulting, medical supply sales and marketing support, management, and capital markets advisory services for select micro, small and medium sized companies within the healthcare and biotech sectors. HSTA Health provides healthcare management and patient services and develops new healthcare technologies for neurological and psychiatric disorders. The Company is positioned to make strategic acquisitions of emerging growth companies with unique sciences and technologies. The Company intends to pursue the acquisition and development of healthcare related technologies in the healthcare and biotech sectors through acquisition, licensing, or joint ventures. The Company will also consider a third avenue of investing in certain technologies. The Company entered the healthcare sector to explore emerging healthcare technologies, especially growth companies that own and develop unique sciences and technologies.
For more information about Hestia Insight, please visit the Company’s website: www.hestiainsight.com
Hestia Insight Investor Relations: investors.hestiainsight.com
Facebook: Hestia Insight Inc.
LinkedIn: Hestia Insight Inc.
Twitter: @HestiaInsight
Hestia Insight is subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended, and, in accordance with the Securities Exchange Act, the Company files periodic reports, documents, and other information with the SEC relating to our business, financial statements, and other matters. These filings are available to the public on the Commission’s website at http://www.sec.gov.
Investor Relations Contact:
Paul Knopick
Tel: 940.262.3584
Email: pknopick@eandecommunications.com
